As shown in Figure 3A, the meta-analysis indicated that the OS for WBRT plus EGFR-TKIs was superior to WBRT alone in NSCLC patients with BM (HR = 0.52 [95% CI 0.37–0.75; P = 0.0004]). This evidence concerns the gene EGFR and non-small cell lung carcinoma.